The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy

Cancer

Volumn 117, Issue 22, 2011, Pages 5039-5046

  Cooperberg, Matthew R ^a   Hilton, Joan F ^a,b   Carroll, Peter R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

prostate neoplasms, radical prostatectomy, risk assessment, prognosis, CaPSURE CAPRA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER OF THE PROSTATE RISK ASSESSMENT SCORE; CANCER PATIENT; CANCER RECURRENCE; CANCER REGISTRY; CANCER RISK; CONTROLLED STUDY; GLEASON SCORE; HAZARD RATIO; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; SCORING SYSTEM; SEMINAL VESICLE;

DISEASE-FREE SURVIVAL; HUMANS; LYMPHATIC METASTASIS; MALE; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE PERIOD; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE; RISK ASSESSMENT; SEMINAL VESICLES; TREATMENT OUTCOME;

EID: 80555123103     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26169     Document Type: Article

References (33)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
2. Cooperberg MR, Pasta DJ, Elkin EP, et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005; 173: 1938-1942. (Pubitemid 40675216)
3. Zhao KH, Hernandez DJ, Han M, Humphreys EB, Mangold LA, Partin AW,. External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score. Urology. 2008; 72 (2): 396-400.
4. Lughezzani G, Budaus L, Isbarn H, Sun M, Perrotte P, Haese A, et al. Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomy. Eur Urol. 2010; 57: 562-568.
5. Cooperberg MR, Freedland SJ, Pasta DJ, et al. Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer. 2006; 107: 2384-2391. (Pubitemid 44748521)
6. May M, Knoll N, Siegsmund M, et al. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a European multicenter survey of 1,296 patients. J Urol. 2007; 178: 1957-1962. (Pubitemid 47538618)
7. Schroeck FR, Aronson WJ, Presti JC Jr, et al. Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone? BJU Int. 2009; 103: 603-608.
8. Cooperberg MR, Broering JM, Carroll PR,. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst. 2009; 101: 878-887.
9. Vickers A,. Prediction models in urology: are they any good, and how would we know anyway? Eur Urol. 2010; 57: 571-573.
10. Cooperberg MR, Hinotsu S, Namiki M, et al. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol. 2009; 27: 4306-4313.
11. Shariat SF, Karakiewicz PI, Roehrborn CG, Kattan MW,. An updated catalog of prostate cancer predictive tools. Cancer. 2008; 113: 3075-3099.
12. Stephenson AJ, Scardino PT, Eastham JA, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2005; 23: 7005-7012.
13. Lubeck DP, Litwin MS, Henning JM, et al. The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology. 1996; 48: 773-777. (Pubitemid 26398700)
14. Cooperberg MR, Broering JM, Litwin MS, et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CaPSURE), a national disease registry. J Urol. 2004; 171: 1393-1401. (Pubitemid 38365382)
15. Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007; 177: 540-545. (Pubitemid 46054056)
16. Harrell FE Jr, Lee KL, Mark DB,. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15: 361-387. (Pubitemid 26072233)
17. Vickers AJ, Elkin EB,. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006; 26: 565-574. (Pubitemid 44728772)
18. Fine JP, Gray RJ,. A proportional hazards model for the subdistribution of competing risk. J Amer Statist Assoc. 1999; 94: 496-509.
19. Cooperberg MR, Broering JM, Carroll PR,. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010; 28: 1117-1123.
20. Penson DF, Chan JM,. Prostate cancer. J Urol. 2007; 177: 2020-2029. (Pubitemid 46735946)
21. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005; 294: 433-439. (Pubitemid 41124175)
22. Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006; 7: 472-479. (Pubitemid 43779173)
23. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009; 181: 956-962.
24. Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007; 25: 2035-2041. (Pubitemid 46972788)
25. Thompson IM, Tangen CM, Klein EA,. Is there a standard of care for pathologic stage T3 prostate cancer? J Clin Oncol. 2009; 27: 2898-2899.
26. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC,. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003; 169: 517-523. (Pubitemid 36132976)
27. Bauer JJ, Connelly RR, Seterhenn IA, et al. Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer. J Urol. 1998; 159: 929-933. (Pubitemid 28106559)
28. Kattan MW, Wheeler TM, Scardino PT,. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999; 17: 1499-1507. (Pubitemid 29220858)
29. Greene KL, Meng MV, Elkin EP, et al. Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE). J Urol. 2004; 171 (6 pt 1): 2255-2259. (Pubitemid 38625446)
30. Burkhard FC, Bader P, Schneider E, Markwalder R, Studer UE,. Reliability of preoperative values to determine the need for lymphadenectomy in patients with prostate cancer and meticulous lymph node dissection. Eur Urol. 2002; 42: 84-90; discussion 90-92.
31. Touijer K, Rabbani F, Otero JR, et al. Standard vs limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1%. J Urol. 2007; 178: 120-124. (Pubitemid 46898466)
32. Mattei A, Fuechsel FG, Bhatta Dhar N, et al. The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol. 2008; 53: 118-125. (Pubitemid 350166722)
33. Sartor O,. Endpoints in prostate cancer clinical trials. Urology. 2002; 60 (3 suppl 1): 101-107.